Annotation Detail
Information
- Associated Genes
- CD274
- Associated Variants
-
CD274 EXPRESSION
CD274 EXPRESSION - Associated Disease
- melanoma
- Source Database
- CIViC Evidence
- Description
- A clinical trial of 86 patients evaluated concurrent (n=53) or sequential (n=33) treatment of ipilimumab (anti-CTLA4) and nivolumab (anti-PD1). In the concurrent regimen cohort, 65% of patients showed clinical activity with no correlation between PD-L1 expression and response (6 of 13 patients were PD-L1 positive versus 9 of 22 patients were PD-L1 negative). In the sequential regimen cohort, 20% of patients had an objective response with a potential correlation between PD-L1 expression and response (4 of 8 patients were PD-L1 positive versus 1 of 13 patients were PD-L1 negative).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1615
- Gene URL
- https://civic.genome.wustl.edu/links/genes/11335
- Variant URL
- https://civic.genome.wustl.edu/links/variants/276
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Melanoma
- Evidence Direction
- Does Not Support
- Drug
- Ipilimumab,Nivolumab
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 23724867
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Ipilimumab | Sensitivity | false |
| Nivolumab | Sensitivity | false |